Validation of the Gugging Swallowing Screen for the Intensive Care Unit
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Aug 25, 2020
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Aetiology of dysphagia after extubation is unknown and considered to be multifactorial. Use of a standardized dysphagia- screening permits an early diagnosis. This study is to evaluate a new GUSS (gugging swallowing Screen) tool with multi-consistency check for intensive care patients (GUSS-ICU) with dysphagia. The concurrent validity (in terms of sensitivity and specificity) of the GUSS-ICU is analyzed in comparison to the flexible endoscopic evaluation of swallowing (FEES).
The GUSS-ICU with multi-consistency check includes an indirect and a direct swallowing attempt. In indirect swallow...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients treated in ICU with intubation time of at least 24 hours
- • Richmond Agitation-Sedation Scale (RASS)-Score of 0 (alert and calm) to 2 (agitated)
- • Inclusion in study not earlier than 1 hour after extubation
- • Mini-Mental-State (MMS) Score \>/=24
- • signed informed consent
- Exclusion Criteria:
- • not capable to follow study procedures (language problems, mental disorder)
- • end of life- patients
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Claudia Troll
Principal Investigator
Logopädie (speech therapy), University Hospital Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials